title: [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
abstract: Among the proteases involved in the tumor invasion process, components of the plasminogen activator system (plasminogen activator type-urokinase uPA, its membrane receptor uPAR and its two inhibitors PAI-1 and PAI-2) appear to define high risk patients in primary breast cancer. As individual analysis of each component of the plasminogen activator system does not reflect the complex interactions between the different components, we studied the prognostic impact of a dissemination risk index combining the four variables. We found that this index was the most powerful prognostic factor, particularly in node-negative patients.
authors.affiliation: Département de biologie, centre René-Huguenin, 35, rue Dailly, 92211 St-Cloud, France.
authors.forename: C
authors.initials: C
authors.lastname: Bouchet
authors.forename: K
authors.initials: K
authors.lastname: Hacène
authors.forename: P M
authors.initials: PM
authors.lastname: Martin
authors.forename: V
authors.initials: V
authors.lastname: Becette
authors.forename: M
authors.initials: M
authors.lastname: Tubiana-Hulin
authors.forename: S
authors.initials: S
authors.lastname: Lasry
authors.forename: J
authors.initials: J
authors.lastname: Oglobine
authors.forename: F
authors.initials: F
authors.lastname: Spyratos
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000601:surgery; D005260:Female; D006801:Humans; D015993:Life Tables; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D017396:Plasminogen Activator Inhibitor 2 / Q000032:analysis*; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D055293:Receptors, Urokinase Plasminogen Activator; D012189:Retrospective Studies; D012306:Risk; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; C524898:PLAUR protein, human; D017395:Plasminogen Activator Inhibitor 1; D017396:Plasminogen Activator Inhibitor 2; D011956:Receptors, Cell Surface; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator